<DOC>
	<DOCNO>NCT01162265</DOCNO>
	<brief_summary>The objective study assess efficacy two current TB ( tuberculosis ) blood test ( Interferon Gamma Release Assays ( IGRA ) ) compare standard skin test ( Mantoux Tuberculin Skin Test ( TST ) ) , predict active tuberculosis among increase risk TB . Those increase risk define either newly arrive immigrant people contact TB case . The study also provide information cost effectiveness different test strategy , two step test approach recommend NICE . The study fund NIHR Health Technology Assessment programme . 10,000 participant recruit 12 hospital network GP surgeries London . All participant skin test blood take assays . Disease status participant follow average 24 month use national register clinical report , phone call national microbiological database . The risk develop active disease high first two year exposure . During followup additional diagnostic procedure unless symptom occur , i.e . line current NICE policy . A sub group patient , select random 25 % participant , repeat IGRA test shortly first test investigate whether skin test affect result blood test .</brief_summary>
	<brief_title>Prognostic Value Interferon Gamma Release Assays Predicting Active Tuberculosis Among Individuals With , Risk , Latent Tuberculosis Infection</brief_title>
	<detailed_description>DESIGN : Prospective cohort study individual ( &gt; = 16 yr ) : ( ) close contact TB case ( b ) new entrant high incidence country ( &gt; 40/100000 ) . SETTING : London TB clinic . NE London TB Network Primary Care Practices . All study site coordinate HPA Centre Infections . HEALTH TECHNOLOGIES ( LTBI MEASURES ) : Participants test Mantoux TST two IGRA test ( Quantiferon-Gold In Tube ELISA ) ELISpot assay ( Tspot.TB ) . A 25ml blood specimen collect residuum , IGRA testing , full blood count repetition indeterminate assay , store future research . All test conduct use standardised protocol . ( 6 ) ACTION AFTER TESTING : This follow exist NICE guidance . ( 1 ; 2 ) A ) If negative TST IGRA , follow . B ) If positive either TST IGRA test , active TB exclude . Those without active TB follow . C ) If positive IGRA &amp; TST test &gt; 35 yr , follow 16-34 yr , chemoprophylaxis offer balanced advice potential benefits/risks . PRIMARY OUTCOME : Development active TB . Prognostic value test quantify incidence rate ratio ( RR ) among contact new entrant . SECONDARY OUTCOME : Side effect chemoprophylaxis . FOLLOW UP : average 24 month date IGRA/TST testing . ) phone call GP patient 24 month . b ) national enhance TB surveillance . c ) national database culture prove TB . ) Clinic record . ADDITIONAL DATA : collect potential source case contact use questionnaire medical record review ( see ) . HIV status determine end follow-up period anonymised record linkage national HIV surveillance system , reliable . ( 4 ) DNA finger print data , national strain type database , utilised ascertain transmission index case subsequent diagnosis among contact . ANALYSIS PLAN : The predictive performance test ( TST , ELISpot ELISA ) summarise RR test positive develop active TB compare ( analogous positive likelihood ratio : TPR/FPR ) . GEE Poisson regression compare disease RRs test account length follow-up exploit within patient comparison test . Absolute risk disease different group describe evidence LTBI LTBI / receive chemoprophylaxis . Other analysis : HIV infect risk factor LTBI . SAMPLE SIZE : Assuming LTBI rate 30 % , 5 % progress active TB 2 year untreated 20 % loss follow-up , simulation indicate cohort 5,000 would 80 % power detect clinically important difference predictive performance ( P &lt; 0.05 ) would arise difference sensitivity specificity 10 % test detect LTBI . 50 % TB contact new entrant age &gt; 35yrs , cohort 10,000 identifies 5,000 primary analysis progression without treatment . Testing follow-up 10,000 would allow appropriately powered secondary analysis ) compare contact immigrant , b ) estimate progression treatment use regression model adjust test dependent treatment decision . ECONOMIC ANALYSIS : The cost-effectiveness alternative screening strategy patient suspect LTBI assess . A decision model develop estimate cost ( Â£ ) health effect ( QALYs ) follow strategy : ) screening , b ) TST alone , c ) different IGRA test ( ELISA ELISpot ) , ) TST follow IGRA positive . These strategy compare : contact new entrant stratify age baseline risk . The model use data cohort study publish literature , follow NICE reference case ( 5 ) . Probabilistic sensitivity analysis use assess uncertainty . Benefits due prevention transmission estimate .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Latent Tuberculosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Contacts active TB ( pulmonary extrapulmonary ) patient . ( Contacts include individual cumulative duration exposure great eight hour relevant index case confine space period infectiousness ( prior initiation treatment ) attend designate clinic . New entrant high incidence country ( incidence TB &gt; 40/100000 ) attend designate clinic Patients unable give inform consent Children 16 year age Individuals find active TB time screen</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>IGRA</keyword>
	<keyword>latent</keyword>
</DOC>